Invex Therapeutics (ASX:IXC) 3-1 Month Momentum %: 33.33% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IXC Invex Therapeutics Ltd ASX:IXC
35 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics 3-1 Month Momentum %?

Invex Therapeutics ASX:IXC 35 3-1 Month Momentum % is 33.33% as of Jul. 14, 2026. GuruFocus rates ASX:IXC with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,385 Biotechnology companies, Invex Therapeutics ranks better than 91.91% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-14), Invex Therapeutics's 3-1 Month Momentum % is 33.33%.

The industry rank for Invex Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

ASX:IXC's 3-1 Month Momentum % is ranked better than
91.91% of 1385 companies
in the Biotechnology industry
Industry Median: -10.59 vs ASX:IXC: 33.33

Invex Therapeutics  (ASX:IXC) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Invex Therapeutics 3-1 Month Momentum % Related Terms

ASX:IXC vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Invex Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's 3-1 Month Momentum % falls into.


ASX:IXC
35GF Score
Invex Therapeutics Ltd ASX:IXC
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics  (ASX:IXC) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 33.33% mean?
Invex Therapeutics (ASX:IXC) has a 3-1 Month Momentum % of 33.33% as of Jul. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Invex Therapeutics and its competitors. According to the industry distribution chart, Invex Therapeutics ranks #112 out of 1385 companies in the Biotechnology industry, placing it in the top 8.1%.
Is Invex Therapeutics' 3-1 Month Momentum % too high?
Invex Therapeutics' current 3-1 Month Momentum % is 33.33%. Based on the distribution chart, Invex Therapeutics ranks #112 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Invex Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #112 out of 1385 companies for 3-1 Month Momentum %. This places Invex Therapeutics in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current 3-1 Month Momentum % is 33.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current 3-1 Month Momentum % of 33.33%. The current 3-1 Month Momentum % is 33.33%. Invex Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current 3-1 Month Momentum % is 33.33% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
35GF Score

Get the complete analysis for ASX:IXC

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price